Evacetrapib vs Placebo: Number of Participants With Composite Endpoint of CV Death, MI, Stroke, or Hospitalization for UA
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0946 | 0.0874 | 0.102 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0942 | 0.0871 | 0.102 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.000415 | -0.01 | 0.0108 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1 | 0.899 | 1.12 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1 | 0.89 | 1.14 | log | ClinicalTrials.gov | |
| Number needed to treat, for one more participant with the outcome on Evacetrapib than on Placebo | 2,410 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Evacetrapib | Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants received standard of care for HRVD. | 571 | 6,038 | OG000 | ClinicalTrials.gov |
| Group 2 | Placebo | Placebo, tablet administered orally once daily for up to 4 years. Participants received standard of care for HRVD. | 570 | 6,054 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Number of Participants With Composite Endpoint of CV Death, MI, Stroke, or Hospitalization for UA | ClinicalTrials.gov |
| Description | For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously. | ClinicalTrials.gov |
| Time frame | Baseline through End of Study (Up to 4 years) | ClinicalTrials.gov |
| Population | All randomized participants. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | A Study of Evacetrapib in High-Risk Vascular Disease | ClinicalTrials.gov |
| NCT number | NCT01687998 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Cardiovascular Diseases | ClinicalTrials.gov |
| Interventions | Evacetrapib, Placebo | ClinicalTrials.gov |
| Lead sponsor | Eli Lilly and Company | ClinicalTrials.gov |
| Results first posted | 2018-05-16 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT01687998?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.